NCT05286164View on ClinicalTrials.gov

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2024

Conditions
CART TreatmentB Cell Lymphoma
Interventions
DRUG

Eltrombopag

Eltrombopag 150 mg QD for 8 weeks

Trial Locations (1)

6423906

RECRUITING

Tel-Aviv Sourasky Medicak center / BMT Unit, Tel Aviv

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV

NCT05286164 - Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | Biotech Hunter | Biotech Hunter